Home/Pipeline/Optimized VHH vs. SARS-CoV-2

Optimized VHH vs. SARS-CoV-2

Infectious Disease

Pre-clinicalActive

Key Facts

Indication

Infectious Disease

Phase

Pre-clinical

Status

Active

Company

Ordaos Bio

About Ordaos Bio

Ordaos Bio is an AI-driven drug design company pioneering a new class of therapeutics called miniPRO™ proteins. Its core technology is a multitask meta-learning Design Engine that generates and optimizes novel protein sequences from scratch, aiming to deliver drug candidates with superior properties in a fraction of the time of traditional methods. The company operates through internal programs and strategic partnerships, positioning itself as an enabler for faster, more efficient development of biologics. While still in the pre-clinical stage, its platform has demonstrated proof-of-concept in generating binders for targets like HER2 and SARS-CoV-2.

View full company profile

Therapeutic Areas

Oncology Infectious Disease

Other Infectious Disease Drugs

Drug	Company	Phase	Status
Vaccine Platform	Biolingus	Research	Active
Pipeline Antibiotics	BioQ Pharma	Unknown	Active
Antivirals Platform	Qubit Pharmaceuticals	Discovery	Active
Antibiotic Development Program	AF ChemPharm	Pre-clinical	Active
Prophylactic Vaccine Development	ImmuneSpec	Service	Active
AmorphOX Vaccine	Orexo	Preclinical	Active (with Abera)
Undisclosed Vaccine Program(s)	Brazos Biomedical	Pre-clinical	Active
Undisclosed Asset 1	Uvax Bio	Research	Active
Undisclosed Asset 2	Uvax Bio	Research	Active
Undisclosed Asset 3	Uvax Bio	Research	Active
Vaccine Immune Response (SARS-CoV-2)	CellChorus	Preclinical	Active
POCKIT™ Central COVID-19 Assay	GeneReach Biotechnology	commercial	Active